Circulating microRNA-141 as a Biomarker for Prostate Cancer: A Systematic Review and Meta-Analysis
1 Department of Biochemistry & Pharmacology, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania; (D.N.); (A.M.); (E.S.); (I.O.S.); (C.M.)
2 Department of Urology, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania;
3 Department of Functional Genomics, Proteomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, 400015 Cluj-Napoca, Romania;
4 Discipline of Public Health and Health Management, Department of Functional Sciences, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania;
5 Center for Translational Research and Systems Medicine, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania
* Correspondence:
* Author to whom correspondence should be addressed.
Received: 22 Nov 2021 / Revised: 5 Aug 2022 / Accepted: 20 Aug 2022 / Published: 23 Sep 2022
Abstract
(1) Background and Objectives: Responding to the need for more optimized biomarkers for prostate cancer (PCa) diagnosis, a high number of studies have shown that microRNAs (miRNAs) could serve as novel, more reliable diagnostic tools. The usefulness of these miRNAs in assessing the presence of PCa is still under debate, given the discrepancies in their diagnostic performances. In this respect, hsa-miR-141 is among the miRNAs of particular interest, being very much investigated in PCa biology. (2) Material and Methods: Here, we provide a meta-analysis of miR-141 data published until May 2019, whose diagnostic accuracy was assessed using the Quality Assessment for Diagnostic Accuracy Studies-2 (QUADAS-2) tool, by analyzing several parameters including sensitivity, specificity, positive likelihood ratio (LR+), negative likelihood ratio (LR-), diagnostic odds ratio (DOR) and the area under the curve (AUC). The six studies that matched our selection and were included in our meta-analysis comprise 283 PCa patients, 114 healthy controls, with 84 patients suffering from benign prostate diseases. (3) Results and Conclusions: Our results indicate a very good diagnostic accuracy for miRNA-141 (0.78 sensitivity, 0.96 specificity, DOR of 89, LR+ of 21, LR- of 0.23 and AUC of 0.87), underlying its utility as a PCa diagnostic biomarker.
Keywords: microRNA; prostate cancer; biomarkers; diagnostic value; miR-141
OPEN ACCESS
This is an open access article distributed under the Creative Commons Attribution
License which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited. (CC BY 4.0).
CITE
Nitusca, D.; Marcu, A.; Seclaman, E.; Bardan, R.; Sirbu, I.O.; Balacescu, O.; Bucur, A.I.; Ursoniu, S.; Marian, C. Circulating microRNA-141 as a Biomarker for Prostate Cancer: A Systematic Review and Meta-Analysis. Timisoara_Med 2022, 2022, 4.
Nitusca D, Marcu A, Seclaman E, Bardan R, Sirbu IO, Balacescu O, Bucur AI, Ursoniu S, Marian C. Circulating microRNA-141 as a Biomarker for Prostate Cancer: A Systematic Review and Meta-Analysis. Timisoara Medical Journal. 2022; 2022(2):4.
Nitusca, Diana; Marcu, Anca; Seclaman, Edward; Bardan, Razvan; Sirbu, Ioan Ovidiu; Balacescu, Ovidiu; Bucur, Adina Ioana; Ursoniu, Sorin; Marian, Catalin. 2022. "Circulating microRNA-141 as a Biomarker for Prostate Cancer: A Systematic Review and Meta-Analysis." Timisoara_Med 2022, no. 2: 4.
Not implemented
SHARE
